ACADIA Pharmaceuticals Inc. (($ACAD)) announced an update on their ongoing clinical study. Study Overview: ACADIA Pharmaceuticals Inc. is ...

Monlunabant shows significant and clinically meaningful weight loss over 16 weeks in patients with obesity and metabolic ...

Corbus Pharmaceuticals ( ($CRBP) ) has shared an announcement. On October 18, 2025, Corbus Pharmaceuticals announced data from its Phase 1/2 ...

Strengthens Viatris' Presence in Japan With the Addition of Two Innovative Assets Targeting Areas of Significant Unmet Medical Need Leverages Existing Infrastructure ...

Strengthens Viatris' Presence in Japan With the Addition of Two Innovative Assets Targeting Areas of Significant Unmet Medical Need Leverages Existing ...

The growing use of GLP-1 receptor agonists may affect the interpretation of oncological FDG PET-CT scans, new research presented today at the 38th Annual Congress of the European Association of ...

aDepartment of Surgery, University of California Irvine School of Medicine, Irvine, CA 92868, USA bDepartment of Medicine (Gastroenterology), University of California Irvine School of Medicine, Irvine ...

Much excitement has built in recent years on the new class of incretin drugs that include glucagon-like-peptide-1 inhibitor (single agonists such as semaglutide) and also dual glucose-dependent ...

You are free to share (copy and redistribute) this article in any medium or format within the parameters below: Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must ...

In this phase 3, multinational, randomized, double-blind trial, we examined the safety and efficacy of once-daily orforglipron at doses of 6 mg, 12 mg, or 36 mg, as compared with placebo (assigned in ...